Scribe Therapeutics, Inc. 8K

Scribe Therapeutics reported Q2 2026 results, initiated a Phase 1 trial for STX-1150, secured CIRM grants for STX-1200 and STX-1400, and completed an upsized IPO and Sanofi private placement that extend its cash runway into 2029.

On September 2, 2026, Scribe Therapeutics Inc. reported its second quarter 2026 financial results and significant recent corporate developments, including the initiation of a first-in-human Phase 1 trial in Australia for its lead in vivo epigenetic CRISPR-based LDL-C lowering candidate STX-1150, the receipt of approximately $25.7 million in non-dilutive grant funding from the California Institute for Regenerative Medicine to advance its STX-1200 (Lp(a)) and STX-1400 (triglycerides) cardiometabolic programs toward anticipated clinical entry as early as 2027, publication of new ELXR platform data highlighting improved potency and safety, and completion of an upsized initial public offering and concurrent private placement to Sanofi that together generated about $155.5 million in gross proceeds, extending the company’s cash runway into the first half of 2029, alongside disclosure of a Q2 2026 net loss of $6.5 million on $1.9 million of collaboration revenue and a cash balance of $43.0 million as of June 30, 2026.

Filing Facts

CIK

1853921

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-380184

Alert Tier

7